You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Economic Burden of Treatment-Resistant Depression
|
|---|---|
| Published in |
Clinical Therapeutics, March 2013
|
| DOI | 10.1016/j.clinthera.2012.09.001 |
| Pubmed ID | |
| Authors |
Natalia Olchanski, Michelle McInnis Myers, Marilyn Halseth, Philip L. Cyr, Lindsay Bockstedt, Thomas F. Goss, Robert H. Howland |
| Abstract |
Major depressive disorder (MDD) is a leading cause of disability, morbidity, and mortality worldwide. The lifetime prevalence in the United States is estimated at 17%. Treatment-resistant depression (TRD) is generally defined as failure to achieve remissions despite adequate treatment. About 30% of patients do not achieve remission after 4 different antidepressant treatment trials. A few studies have examined the economic burden of TRD, but none has investigated the cost associated with more chronic and extensive forms of TRD characterized by nonresponse to ≥4 treatment trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 177 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| Canada | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 173 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 29 | 16% |
| Student > Master | 15 | 8% |
| Student > Doctoral Student | 15 | 8% |
| Researcher | 14 | 8% |
| Other | 13 | 7% |
| Other | 32 | 18% |
| Unknown | 59 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 20% |
| Psychology | 18 | 10% |
| Neuroscience | 17 | 10% |
| Biochemistry, Genetics and Molecular Biology | 9 | 5% |
| Social Sciences | 7 | 4% |
| Other | 27 | 15% |
| Unknown | 64 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2014.
All research outputs
#20,655,488
of 25,371,288 outputs
Outputs from Clinical Therapeutics
#2,628
of 3,850 outputs
Outputs of similar age
#160,963
of 208,873 outputs
Outputs of similar age from Clinical Therapeutics
#30
of 50 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,850 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,873 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.